"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 11 | 13 |
| 2011 | 3 | 7 | 10 |
| 2012 | 6 | 8 | 14 |
| 2013 | 6 | 12 | 18 |
| 2014 | 7 | 11 | 18 |
| 2015 | 12 | 6 | 18 |
| 2016 | 14 | 16 | 30 |
| 2017 | 9 | 14 | 23 |
| 2018 | 18 | 11 | 29 |
| 2019 | 13 | 7 | 20 |
| 2020 | 23 | 21 | 44 |
| 2021 | 27 | 26 | 53 |
| 2022 | 7 | 44 | 51 |
| 2023 | 4 | 45 | 49 |
| 2024 | 13 | 10 | 23 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fc? receptors during acute SHIVAD8-EO infection. Nat Commun. 2024 Aug 29; 15(1):7461.
-
Robust SARS-CoV-2-neutralizing antibodies sustained through 6?months post XBB.1.5 mRNA vaccine booster. Cell Rep Med. 2024 Sep 17; 5(9):101701.
-
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds. J Pediatric Infect Dis Soc. 2024 Aug 24; 13(8):421-429.
-
Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis. JCI Insight. 2024 Aug 01; 9(18).
-
Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine. Nat Commun. 2024 Jul 30; 15(1):6421.
-
Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters. Nat Commun. 2024 Jul 23; 15(1):6193.
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 Jun 14; 78(6):1757-1768.
-
Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies. Nat Microbiol. 2024 Aug; 9(8):2128-2143.
-
SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1. Emerg Microbes Infect. 2024 Dec; 13(1):2359004.
-
Human neutralizing antibodies target a conserved lateral patch on H7N9 hemagglutinin head. Nat Commun. 2024 May 27; 15(1):4505.